TSX Venture Exchange: ARI TORONTO, March 9 /CNW/ - ARIUS Research Inc. (TSX-VE: ARI) announced today that it has received notice from the United States Patent and Trademark Office that U.S. patent No. 7,009,040 was issued on March 7, 2006 for ARIUS' lead anti-CD63 antibody, AR7BD-33-11A. Previously ARIUS announced that it had received a Notice of Allowance in October 2005. The patent covers the antibody molecule, various uses of the antibody, its derivatives, and a method for using it, and other similar antibodies, to treat cancers such as prostate and breast cancer. ARIUS has several additional patent applications pending that will continue to enhance the value of this and other important antibody assets. AR7BD-33-11A is one of a series of anti-CD63 antibodies generated through ARIUS' proprietary FunctionFIRST(TM) product platform. ARIUS has shown that antibodies directed against the CD63 target have a significant impact on cancers such as human pancreatic cancer, melanoma, breast and prostate cancers. Due to its potency, and other desirable characteristics, AR7BD-33-11A was selected as a lead antibody and humanized to make it suitable for human clinical trials. "Patents are key to ARIUS' commercial success," commented Dr. David S. Young, President and Chief Scientific Officer of ARIUS, "Issued patents also help validate our technology and demonstrate the inventiveness of our science." About ARIUS Research ARIUS Research Inc. is a biotechnology company dedicated to personalizing cancer therapy through the discovery and development of novel anticancer monoclonal antibodies (MAbs). Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies powerful MAbs targeting a variety of cancer indications. This antibody generation engine has enabled ARIUS to assemble a growing pipeline, which is used for commercial collaborations and in-house development. ARIUS has ongoing partnerships with key biotechnology and drug development companies. The company is listed on the TSX Venture Exchange under the symbol "ARI". Forward-Looking Statement Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in the Company's Annual Report, forthcoming news releases and other filings with Canadian securities regulatory authorities and the U.S. Securities & Exchange Commission. Forward-looking statements are based on our current expectations and ARIUS is not obligated to update such information to reflect later events or developments. Web site: www.ariusresearch.com The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.